Tilray Brands Inc (NASDAQ: TLRY) on Friday, plunged -18.10% from the previous trading day, before settling in for the closing price of $2.1. Within the past 52 weeks, TLRY’s price has moved between $0.35 and $2.32.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -2.69%. The company achieved an average annual earnings per share of 98.43%.
Tilray Brands Inc (TLRY) Insider and Institutional Ownership
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Tilray Brands Inc is 0.96%, while institutional ownership is 9.36%. The most recent insider transaction that took place on Jul 31 ’25, was worth 3,496. In this transaction Global General Counsel of this company bought 6,000 shares at a rate of $0.58, taking the stock ownership to the 698,287 shares. Before that another transaction happened on Jul 30 ’25, when Company’s President and CEO bought 165,000 for $0.61, making the entire transaction worth $100,106. This insider now owns 3,941,633 shares in total.
Tilray Brands Inc (TLRY) Latest Financial update
As on 11/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0 earnings per share (EPS) for the period topping the consensus outlook (set at -0.01) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 98.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 91.25% during the next five years compared to -2.69% drop over the previous five years of trading.
Tilray Brands Inc (NASDAQ: TLRY) Trading Performance Indicators
Tilray Brands Inc (TLRY) is currently performing well based on its current performance indicators. A quick ratio of 1.56 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.27, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach -0.03 in one year’s time.
